Study Summary
This trial is testing a new drug for people with relapsed or refractory B-cell NHL or CLL. The goal is to find the best dose and schedule for the drug and to characterize its safety.
- Non-Hodgkin Lymphoma
- Chronic B-Cell Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 7 Secondary · Reporting Duration: Predose, 48 hours postdose (up to 2 years 10 months)
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Part A: Dose Escalation
1 of 2
Part B: Cohort Expansion
1 of 2
Experimental Treatment
200 Total Participants · 2 Treatment Groups
Primary Treatment: JNJ-75348780 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the current recruitment number for this clinical experiment?
"Affirmative. According to the clinicaltrials.gov website, this trial posted on November 20th 2020 is actively recruiting patients for participation. The study requires 120 individuals from 4 distinct sites in order to proceed as planned." - Anonymous Online Contributor
What is the main objective of this research?
"The primary endpoint of this medical trial, which will be monitored for a period up to two years and ten months, is the number of participants experiencing dose-limiting toxicity. Secondary endpoints include duration of response (DOR), time to response (TTR) and Minimum Observed Serum Concentration (Cmin)of JNJ-75348780." - Anonymous Online Contributor
Is there an opportunity to join this research project at present?
"Affirmative. Clinicaltrials.gov presents evidence that this clinical trial is currently open for enrolment; the initial post was on November 20th 2020, and the study has been updated as of November 3rd 2022. A total of 120 participants have to be recruited from 4 distinct medical sites." - Anonymous Online Contributor
Has the FDA affirmed JNJ-75348780 for use?
"Our team at Power assigned JNJ-7534870 a score of 1 because it is currently being tested in Phase 1 clinical trials. As such, there is minimal data supporting the safety and efficacy of this drug." - Anonymous Online Contributor
How many venues is this experiment overseen in?
"This research project is recruiting from 4 sites; Oklahoma City, New York, Houston and other locales. To minimize the burden of travel for participating individuals it is advisable to select a location nearby." - Anonymous Online Contributor